Literature DB >> 12393483

Cell cycle deregulation in B-cell lymphomas.

Margarita Sánchez-Beato1, Abel Sánchez-Aguilera, Miguel A Piris.   

Abstract

Disruption of the physiologic balance between cell proliferation and death is a universal feature of all cancers. In general terms, human B-cell lymphomas can be subdivided into 2 main groups, low- and high-growth fraction lymphomas, according to the mechanisms through which this imbalance is achieved. Most types of low-growth fraction lymphomas are initiated by molecular events resulting in the inhibition of apoptosis, such as translocations affecting BCL2, in follicular lymphoma, or BCL10 and API2/MLT1, in mucosa-associated lymphoid tissue (MALT) lymphomas. This results in cell accumulation as a consequence of prolonged cell survival. In contrast, high-growth fraction lymphomas are characterized by an enhanced proliferative activity, as a result of the deregulation of oncogenes with cell cycle regulatory functions, such as BCL6, in large B-cell lymphoma, or c-myc, in Burkitt lymphoma. Low- and high-growth fraction lymphomas are both able to accumulate other alterations in cell cycle regulation, most frequently involving tumor suppressor genes such as p16(INK4a), p53, and p27(KIP1). As a consequence, these tumors behave as highly aggressive lymphomas. The simultaneous inactivation of several of these regulators confers increased aggressivity and proliferative advantage to tumoral cells. In this review we discuss our current knowledge of the alterations in each of these pathways, with special emphasis on the deregulation of cell cycle progression, in an attempt to integrate the available information within a global model that describes the contribution of these molecular changes to the genesis and progression of B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393483     DOI: 10.1182/blood-2002-07-2009

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  88 in total

1.  Dysregulation of miRNAs in AL amyloidosis.

Authors:  Liangping Weng; Brian H Spencer; Pamela T SoohHoo; Lawreen H Connors; Carl J O'Hara; David C Seldin
Journal:  Amyloid       Date:  2011-08-11       Impact factor: 7.141

2.  miR-15a enhances the anticancer effects of cisplatin in the resistant non-small cell lung cancer cells.

Authors:  Vildan Bozok Çetintaş; Aslı Tetik Vardarlı; Zekeriya Düzgün; Burçin Tezcanlı Kaymaz; Eda Açıkgöz; Hüseyin Aktuğ; Buket Kosova Can; Cumhur Gündüz; Zuhal Eroğlu
Journal:  Tumour Biol       Date:  2015-08-28

Review 3.  MicroRNA and AU-rich element regulation of prostaglandin synthesis.

Authors:  Ashleigh E Moore; Lisa E Young; Dan A Dixon
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 4.  Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications.

Authors:  George A Calin; Carlo M Croce
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 5.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

6.  Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.

Authors:  Dana J Wallace; DeFen Shen; George F Reed; Masaru Miyanaga; Manabu Mochizuki; H Nida Sen; Samuel S Dahr; Ronald R Buggage; Robert B Nussenblatt; Chi-Chao Chan
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

Review 7.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

8.  The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.

Authors:  Monica Cardone; Ayten Kandilci; Cintia Carella; Jonas A Nilsson; Jennifer A Brennan; Sema Sirma; Ugur Ozbek; Kelli Boyd; John L Cleveland; Gerard C Grosveld
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

9.  Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.

Authors:  Sharvil P Patel; R Andrew Harkins; Michelle J Lee; Christopher R Flowers; Jean L Koff
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-12-24

10.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.

Authors:  Leandro C Cerchietti; Jose M Polo; Gustavo F Da Silva; Pedro Farinha; Rita Shaknovich; Randy D Gascoyne; Steven F Dowdy; Ari Melnick
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.